Bevacizumab - Wirklich effektiv?

The key finding of this study was that, in the overall population, there was a statistically significant benefit from the addition of bevacizumab to fluorouracil-based chemotherapy. However, this benefit was felt to be “modest” and “no more than marginally effective.” Moreover, subset analyses found little to no benefit in patients treated with oxaliplatin. These findings, or at least the conclusions, seem to depart from the majority of previously published data from randomized controlled clinical trials (RCTs), registries, and meta-analyses, including those that have focused on elderly patients.^2–13 How can this discordance be reconciled? Mehr